Viking Therapeutics
VKTX
$76.97
Share price
1.60%
Change (1 day)
236.70%
Change (1 year)
Categories
Viking Therapeutics (VKTX) - Total liabilities
Total liabilities on the balance sheet as of March 2024 : $33.62 M
According to Viking Therapeutics 's latest financial reports the company's total liabilities are $33.62 M. A company’s total liabilities is the sum of all current and non-current debts and obligations.
Viking Therapeutics - Total liabilities on balance sheet (from 2014 to 2024)
Total liabilities by year
| Year | Total liabilities | Change |
|---|---|---|
| 2023-12-31 | $20.07 M | -13.51% |
| 2022-12-31 | $23.2 M | 164.38% |
| 2021-12-31 | $8.77 M | -27.8% |
| 2020-12-31 | $12.15 M | 70.35% |
| 2019-12-31 | $7.13 M | 56.44% |
| 2018-12-31 | $4.56 M | -47.3% |
| 2017-12-31 | $8.65 M | 33.33% |
| 2016-12-31 | $6.49 M | -3.3% |
| 2015-12-31 | $6.71 M | -73.33% |
| 2014-12-31 | $25.17 M | 5740.32% |
| 2013-12-31 | $0.43 M | 308.86% |
| 2012-12-31 | $0.1 M |
Total liabilities for similar companies or competitors
| Company | Total liabilities | differencediff. | Country |
|---|---|---|---|
 Ultragenyx RARE | $1.21 B | 3,515.06% | 🇺🇸 USA |
 Repligen
RGEN | $0.85 B | 2,437.35% | 🇺🇸 USA |